MA41108B1 - Compositions anticancéreuses - Google Patents
Compositions anticancéreusesInfo
- Publication number
- MA41108B1 MA41108B1 MA41108A MA41108A MA41108B1 MA 41108 B1 MA41108 B1 MA 41108B1 MA 41108 A MA41108 A MA 41108A MA 41108 A MA41108 A MA 41108A MA 41108 B1 MA41108 B1 MA 41108B1
- Authority
- MA
- Morocco
- Prior art keywords
- arn
- prostate cancer
- meth
- poly
- hormone
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000001093 anti-cancer Effects 0.000 title 1
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 abstract 6
- 229920000193 polymethacrylate Polymers 0.000 abstract 5
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 abstract 4
- 239000007962 solid dispersion Substances 0.000 abstract 3
- 206010060862 Prostate cancer Diseases 0.000 abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 2
- 230000001394 metastastic effect Effects 0.000 abstract 2
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001125 extrusion Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 230000000683 nonmetastatic effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des formulations pharmaceutiques d'arn-509, qui peuvent être administrées à un mammifère, en particulier à un humain, souffrant d'une maladie ou d'une pathologie associée au récepteur des androgènes (ar), en particulier du cancer, plus particulièrement du cancer de la prostate, y compris mais de façon non limitative, du cancer de la prostate hormono-résistant, du cancer métastatique de la prostate hormono-résistant, du cancer métastatique de la prostate hormono-résistant qui n'a jamais été traité par chimiothérapie, d'une rechute biochimique du cancer de la prostate hormono-sensible, ou du cancer de la prostate hormono-résistant non métastatique à risque élevé. Selon un aspect, ces formulations comprennent une dispersion solide d'arn-509 et d'un copolymère de poly(méth)acrylate. Selon un aspect, la dispersion solide d'arn-509 et d'un copolymère de poly(méth)acrylate peut être obtenue, en particulier est obtenue, par extrusion à l'état fondu d'un mélange comprenant l'arn-509 et un copolymère de poly(méth)acrylate et ensuite éventuellement par broyage dudit mélange extrudé à l'état fondu. Selon un aspect, la dispersion solide d'arn-509 et d'un copolymère de poly(méth)acrylate peut être obtenue, en particulier est obtenue, par séchage par pulvérisation d'un mélange comprenant l'arn-509 et un copolymère de poly(méth)acrylate dans un solvant approprié.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196591 | 2014-12-05 | ||
| PCT/US2015/063667 WO2016090101A1 (fr) | 2014-12-05 | 2015-12-03 | Compositions anticancéreuses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41108A MA41108A (fr) | 2016-06-09 |
| MA41108B1 true MA41108B1 (fr) | 2021-03-31 |
Family
ID=52006905
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055404A MA55404A (fr) | 2014-12-05 | 2015-12-03 | Compositions anticancéreuses |
| MA41108A MA41108B1 (fr) | 2014-12-05 | 2015-12-03 | Compositions anticancéreuses |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055404A MA55404A (fr) | 2014-12-05 | 2015-12-03 | Compositions anticancéreuses |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20170360707A1 (fr) |
| EP (2) | EP3842034B1 (fr) |
| JP (1) | JP6767368B2 (fr) |
| KR (1) | KR102348325B1 (fr) |
| CN (2) | CN106999430A (fr) |
| AR (1) | AR102924A1 (fr) |
| AU (1) | AU2015358493B2 (fr) |
| CA (1) | CA2969661C (fr) |
| CL (1) | CL2017001372A1 (fr) |
| CO (1) | CO2017005573A2 (fr) |
| CR (1) | CR20170217A (fr) |
| CY (1) | CY1123856T1 (fr) |
| DK (1) | DK3226842T3 (fr) |
| EA (1) | EA035988B1 (fr) |
| ES (2) | ES2839128T3 (fr) |
| HR (1) | HRP20201902T1 (fr) |
| HU (1) | HUE051888T2 (fr) |
| IL (1) | IL252324B (fr) |
| LT (1) | LT3226842T (fr) |
| MA (2) | MA55404A (fr) |
| MD (1) | MD3226842T2 (fr) |
| MX (1) | MX384382B (fr) |
| NI (1) | NI201700069A (fr) |
| PL (1) | PL3226842T3 (fr) |
| PT (1) | PT3226842T (fr) |
| RS (1) | RS61466B1 (fr) |
| SG (1) | SG11201704264UA (fr) |
| SI (1) | SI3226842T1 (fr) |
| TW (1) | TWI683662B (fr) |
| UA (1) | UA121123C2 (fr) |
| WO (1) | WO2016090101A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ744456A (en) | 2012-09-26 | 2019-09-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| SG11201704267VA (en) | 2014-12-05 | 2017-06-29 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| HUE054935T2 (hu) | 2014-12-05 | 2021-10-28 | Aragon Pharmaceuticals Inc | Rákellenes készítmények |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| ES2967689T3 (es) * | 2018-04-06 | 2024-05-03 | Capsugel Belgium Nv | Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)] |
| WO2020144650A1 (fr) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Anti-androgènes pour le traitement du cancer de la prostate |
| KR20210122275A (ko) | 2019-01-30 | 2021-10-08 | 얀센 파마슈티카 엔.브이. | 분자 아형에 기초하여 전립선암을 치료하는 방법 |
| EP3917519A1 (fr) | 2019-01-30 | 2021-12-08 | Aragon Pharmaceuticals, Inc. | Anti-androgènes pour le traitement du cancer de la prostate métastatique sensible à la castration |
| WO2020239478A1 (fr) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectédine pour le traitement de sarcomes basé sur des marqueurs génomiques |
| US11723898B2 (en) | 2019-11-04 | 2023-08-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (fr) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires |
| WO2022049523A1 (fr) | 2020-09-04 | 2022-03-10 | Aragon Pharmaceuticals, Inc. | Méthodes de traitement du cancer de la prostate |
| WO2022195407A1 (fr) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Méthodes de traitement du cancer de la prostate |
| WO2023152611A1 (fr) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide et relugolix pour le traitement du cancer de la prostate |
| WO2023209555A1 (fr) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Produits médicamenteux approuvés et méthodes de traitement du cancer de la prostate |
| CN121038790A (zh) | 2023-03-16 | 2025-11-28 | 拜耳消费者护理股份有限公司 | 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂 |
| WO2026052846A1 (fr) | 2024-09-09 | 2026-03-12 | Synthon B.V. | Formulation pharmaceutique comprenant de l'apalutamide |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1381358B1 (fr) | 2001-04-02 | 2006-05-03 | Astrazeneca AB | Composition pharmaceutique solide contenant 4-cyano-trifluoro-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropiono-m-toluidiure et pvp |
| WO2003077827A1 (fr) * | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Procede de production de medicament solide en dispersion |
| AU2003292509B2 (en) * | 2003-12-15 | 2007-08-02 | Council Of Scientific And Industrial Research | Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer |
| SI2656842T1 (sl) * | 2006-03-27 | 2016-10-28 | The Regents Of The University Of California | Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji |
| AU2011218173C1 (en) * | 2010-02-16 | 2015-04-16 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| WO2012174436A1 (fr) * | 2011-06-15 | 2012-12-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulateurs de récepteurs nucléaires et leur utilisation pour le traitement et la prévention d'un cancer |
| WO2013152342A1 (fr) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Inhibiteur de mtor anticancéreux et combinaison anti-androgène |
| EP2858985B1 (fr) | 2012-06-07 | 2018-04-18 | Aragon Pharmaceuticals, Inc. | Formes cristallines d'un modulateur du récepteur des androgènes |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| JP6404217B2 (ja) * | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| NZ744456A (en) * | 2012-09-26 | 2019-09-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| PL2945628T3 (pl) * | 2013-01-15 | 2020-09-21 | Aragon Pharmaceuticals, Inc. | Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza |
| WO2014114575A1 (fr) * | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Composition pharmaceutique à biodisponibilité ameliorée |
| WO2014167428A2 (fr) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | 4-(3-(4-cyano-3-(trifluorométhyl)phényl)-5,5-diméthyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-méthylbenzamide amorphe |
| CN105636594A (zh) * | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 |
| WO2015118015A1 (fr) * | 2014-02-05 | 2015-08-13 | Lek Pharmaceuticals D.D. | Compositions pharmaceutiques solides d'antagonistes du récepteur des androgènes |
-
2015
- 2015-12-03 LT LTEP15817642.0T patent/LT3226842T/lt unknown
- 2015-12-03 EP EP20209559.2A patent/EP3842034B1/fr active Active
- 2015-12-03 US US15/533,203 patent/US20170360707A1/en not_active Abandoned
- 2015-12-03 CN CN201580066192.9A patent/CN106999430A/zh active Pending
- 2015-12-03 CA CA2969661A patent/CA2969661C/fr active Active
- 2015-12-03 EP EP15817642.0A patent/EP3226842B1/fr active Active
- 2015-12-03 JP JP2017529637A patent/JP6767368B2/ja active Active
- 2015-12-03 UA UAA201707016A patent/UA121123C2/uk unknown
- 2015-12-03 CN CN202211487545.0A patent/CN115837010B/zh active Active
- 2015-12-03 CR CR20170217A patent/CR20170217A/es unknown
- 2015-12-03 PT PT158176420T patent/PT3226842T/pt unknown
- 2015-12-03 DK DK15817642.0T patent/DK3226842T3/da active
- 2015-12-03 MD MDE20170153T patent/MD3226842T2/ro not_active IP Right Cessation
- 2015-12-03 MA MA055404A patent/MA55404A/fr unknown
- 2015-12-03 TW TW104140458A patent/TWI683662B/zh not_active IP Right Cessation
- 2015-12-03 ES ES15817642T patent/ES2839128T3/es active Active
- 2015-12-03 MA MA41108A patent/MA41108B1/fr unknown
- 2015-12-03 SG SG11201704264UA patent/SG11201704264UA/en unknown
- 2015-12-03 HU HUE15817642A patent/HUE051888T2/hu unknown
- 2015-12-03 PL PL15817642T patent/PL3226842T3/pl unknown
- 2015-12-03 RS RS20210184A patent/RS61466B1/sr unknown
- 2015-12-03 WO PCT/US2015/063667 patent/WO2016090101A1/fr not_active Ceased
- 2015-12-03 MX MX2017007201A patent/MX384382B/es unknown
- 2015-12-03 SI SI201531519T patent/SI3226842T1/sl unknown
- 2015-12-03 EA EA201791252A patent/EA035988B1/ru unknown
- 2015-12-03 HR HRP20201902TT patent/HRP20201902T1/hr unknown
- 2015-12-03 ES ES20209559T patent/ES3021508T3/es active Active
- 2015-12-03 AU AU2015358493A patent/AU2015358493B2/en active Active
- 2015-12-03 KR KR1020177018240A patent/KR102348325B1/ko active Active
- 2015-12-04 AR ARP150103980A patent/AR102924A1/es unknown
-
2017
- 2017-05-16 IL IL252324A patent/IL252324B/en unknown
- 2017-05-29 CL CL2017001372A patent/CL2017001372A1/es unknown
- 2017-06-02 NI NI201700069A patent/NI201700069A/es unknown
- 2017-06-05 CO CONC2017/0005573A patent/CO2017005573A2/es unknown
-
2021
- 2021-01-27 CY CY20211100068T patent/CY1123856T1/el unknown
- 2021-12-13 US US17/549,495 patent/US20220151931A1/en not_active Abandoned
-
2024
- 2024-05-10 US US18/661,226 patent/US20240293321A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41108B1 (fr) | Compositions anticancéreuses | |
| MA41111B1 (fr) | Compositions anticancéreuses | |
| MA41107B1 (fr) | Compositions anti-cancéreuses | |
| MA42439B1 (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA38170A1 (fr) | Nouveaux acides indanyloxydihydrobenzofuranylacétiques | |
| FR3031108B1 (fr) | Composition comprenant un polymere a phases multiples, son procede de preparation et son utlisation | |
| MA38493A1 (fr) | Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane | |
| MA55082A (fr) | Compositions, procédés, et kits pour l'administration de polyribonucléotides | |
| MA41547B1 (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie | |
| MA52856B1 (fr) | Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 | |
| FR2958284B1 (fr) | Melange fluidifiant pour composition hydraulique | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| FR3029790B1 (fr) | Microbille d'hydrogel de chitosane | |
| MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
| AU2017275396A1 (en) | Anticancer compositions | |
| EP3689908A4 (fr) | Anticorps anti-bcma ayant une affinité élevée pour bcma et composition pharmaceutique pour le traitement du cancer, comprenant celui-ci | |
| MA43400B1 (fr) | Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2 | |
| EP2331092A4 (fr) | Procédés et compositions pour l'administration de 3-halopyruvate et de composés associés pour le traitement du cancer | |
| MA45748A (fr) | Conjugués d'acide hyaluronique et de composés anticancéreux. | |
| EP3865141A4 (fr) | Agent anticancéreux, composition pharmaceutique pour le traitement du cancer et kit | |
| MA40599A1 (fr) | Formulations injectables de paracétamol | |
| EP2415482A4 (fr) | Compositions pharmaceutiques pour le traitement d'une métastase | |
| EP3972981A4 (fr) | Complexes d'or-carbène-naphtoquinone fonctionnalisés destinés à être utilisés dans le traitement du cancer | |
| MA34795B1 (fr) | Composition pharmaceutique solide pour administration buccale d'agomelatine |